Refined-JinQi-JiangTang tablet ameliorates hypertension through activation of FGF21/FGFR1 axis in fructose-fed rats
- PMID: 35534765
- DOI: 10.1007/s11418-022-01626-1
Refined-JinQi-JiangTang tablet ameliorates hypertension through activation of FGF21/FGFR1 axis in fructose-fed rats
Abstract
The aim of this study was to investigate the therapeutic effect of JQ-R on metabolic hypertension and its correlation with Fibroblast growth factor 21/Fibroblast growth factor receptors 1(FGF21/FGFR1) pathway. In this study, fructose-induced metabolic hypertension rats were used as hypertension models to detect the regulation effect of JQ-R on hypertension. The effects of JQ-R on blood glucose, blood lipids, serum insulin levels and other metabolic indicators of rats were also measured. The effects of JQ-R on FGF21/FGFR1 signaling pathway in model animals were detected by Real-time quantitative PCR and Western blotting. The results showed that JQ-R significantly reduce the blood pressure of model rats in a dose-dependent manner. Meanwhile, fasting insulin, fasting blood glucose, insulin resistance index, total cholesterol and triglyceride levels were significantly decreased, and glucose and lipid metabolism abnormalities were also significantly improved. JQ-R induces these changes along with FGFR1 phosphorylation, which was also detected in JQ-R treated FGF21 knockout mice. These results suggest that JQ-R can reduce blood pressure and improve glucose and lipid metabolism in fructose-induced hypertension rats. Activation of FGF21/FGFR1 signaling pathway to regulate downstream blood pressure and glucolipid metabolism-related pathways may be one of the important mechanisms of JQ-R in regulating blood pressure.
Keywords: ACE2; Akt; FGF21/FGFR1 axis; Metabolic hypertension; Refined-JinQi-JiangTang tablets (JQ-R).
© 2022. The Author(s) under exclusive licence to The Japanese Society of Pharmacognosy.
References
-
- Holmes E, Loo RL, Stamler J et al (2008) Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453:396–400. https://doi.org/10.1038/nature06882 - DOI - PubMed - PMC
-
- Xu WL, Janocha AJ, Erzurum SC (2021) Metabolism in pulmonary hypertension. Annu Rev Physiol 83:551–576. https://doi.org/10.1146/annurev-physiol-031620-123956 - DOI - PubMed - PMC
-
- Chaudhary K, Buddineni JP, Nistala R et al (2011) Resistant hypertension in the high-risk metabolic patient. Curr Diab Rep 11(1):41–46. https://doi.org/10.1007/s11892-010-0155-x - DOI - PubMed
-
- Chakraborty S, Mandal J, Yang T et al (2020) Metabolites and hypertension: insights into hypertension as a metabolic disorder: 2019 harriet dustan award. Hypertension 75(6):1386–1396. https://doi.org/10.1161/HYPERTENSIONAHA.120.13896 - DOI - PubMed
-
- Whelton PK, Carey RM, Aronow WS et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71(19): e127-e248. Doi: https://doi.org/10.1016/j.jacc.2017.11.006
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
